AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7917369 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose carboplatin and radiotherapy
Number of subjects: 55
Study 3045901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 1% (group 1)
Number of subjects: 60
Study 3045901 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine 1% (group 2)
Number of subjects: 60
Study 31977865 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day plus HAD-B1 972 mg
Number of subjects: 66
Study 31977865 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day plus HAD-B1 1944 mg
Number of subjects: 66
Study 31977865 — intervention group
Group type: COMPARATOR
Intervention: Afatinib 40 mg/day
Number of subjects: 66
Study 29457215 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-paravertebral anaesthesia
Number of subjects: 397
Study 29457215 — intervention group
Group type: COMPARATOR
Intervention: Inhalational agent-opioid anaesthesia
Number of subjects: 397
Study 26099910 — intervention group
Group type: EXPERIMENTAL
Intervention: Jigsaw method (peer-assisted learning)
Number of subjects: 137
Study 26099910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation group (VEN)
Number of subjects: 137
Study 26099910 — intervention group
Group type: COMPARATOR
Intervention: Control group (expert instruction)
Number of subjects: 137
Study 25662002 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic taping over the thoracic spine
Number of subjects: 10
Study 25662002 — intervention group
Group type: COMPARATOR
Intervention: No intervention (pre-intervention state)
Number of subjects: 10
Study 23921860 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine submucosal injection (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 101
Study 23921860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (four puffs of 10% lidocaine)
Number of subjects: 101
Study 21751432 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate 50/100 µg bd (SFC)
Number of subjects: 548
Study 21751432 — intervention group
Group type: COMPARATOR
Intervention: Montelukast 5 mg od (MON)
Number of subjects: 548
Study 21751432 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 548
Study 21751432 — intervention group
Group type: COMPARATOR
Intervention: MON
Number of subjects: 548
Study 18154127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicarbamin 100 mg/day
Number of subjects: 33
Study 18154127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicarbamin
Number of subjects: 33
Study 18154127 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy plus dicarbamin
Number of subjects: 33
Study 15564817 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive intervention program (n = 42)
Number of subjects: 97
Study 15564817 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (n = 40)
Number of subjects: 97
Study 15564817 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 15)
Number of subjects: 97
Study 11523070 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9684947 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum extract with 5.0% hyperforin, once a day for 8 days
Number of subjects: 54
Study 9684947 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum extract with 0.5% hyperforin, once a day for 8 days
Number of subjects: 54
Study 9684947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8022682 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 36
Study 8022682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no caffeine)
Number of subjects: 36
Study 2736988 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA (5 g prior to skin incision, followed by 1 g/h for 6 to 8 h)
Number of subjects: 350
Study 2736988 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 350
Study 2736988 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution administered in the same fashion)
Number of subjects: 350
Study 2736988 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 350
Study 1097628 — intervention group
Group type: EXPERIMENTAL
Intervention: Test mouthrinse (Cepacol)
Number of subjects: 10
Study 1097628 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 10
Study 29281101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (40 mg three times daily)
Number of subjects: 200
Study 29281101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26252526 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVMAG (x3) prime-Ad35 (x1) boost
Number of subjects: 75
Study 26252526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35 boost
Number of subjects: 75
Study 26252526 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVMAG (x3) with or without IL-12
Number of subjects: 75
Study 26252526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 26252526 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVMAG (x3) with IL-12
Number of subjects: 75
Study 24437301 — intervention group
Group type: EXPERIMENTAL
Intervention: Impression technique with a tissue-stop area
Number of subjects: 20
Study 24437301 — intervention group
Group type: COMPARATOR
Intervention: Traditional impression technique
Number of subjects: 20
Study 21382515 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening or headphones only for noise cancellation
Number of subjects: 0
Study 18326282 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg a day for 4 months
Number of subjects: 35
Study 18326282 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan in combination with non-drug means
Number of subjects: 35
Study 16585984 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm UVB therapy
Number of subjects: 10
Study 16585984 — intervention group
Group type: COMPARATOR
Intervention: cream PUVA therapy
Number of subjects: 10
Study 15173792 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoloop ligation
Number of subjects: 50
Study 15173792 — intervention group
Group type: COMPARATOR
Intervention: Elastic band ligation
Number of subjects: 50
Study 11479157 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C
Number of subjects: 49
Study 11479157 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 49
Study 11479157 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta(2)-microglobulin
Number of subjects: 49
Study 10186459 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone
Number of subjects: 100000
Study 10186459 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen
Number of subjects: 100000
Study 7926499 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distention
Number of subjects: 10
Study 7926499 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 10
Study 7926499 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal distention
Number of subjects: 10
Study 7926499 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric relaxatory responses to duodenal distention
Number of subjects: 10
Study 2577116 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 10
Study 2577116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 234488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine HCl (Benadryl)
Number of subjects: 28
Study 234488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (Periactin)
Number of subjects: 28
Study 234488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine HCl (Atarax)
Number of subjects: 28
Study 234488 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 28
Study 31257168 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 JAU of JC pollen (A)
Number of subjects: 1042
Study 31257168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 1042
Study 27903842 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle change intervention (diet, exercise, mind-body practice, behavioral counseling) during radiotherapy and for 12 months after
Number of subjects: 55
Study 27903842 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person lifestyle counseling (42 hours during XRT)
Number of subjects: 55
Study 27903842 — intervention group
Group type: EXPERIMENTAL
Intervention: Video counseling (up to 30 hours over 12 months)
Number of subjects: 55
Study 27903842 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection from exit interviews and other sources
Number of subjects: 55
Study 24867068 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 75 mg once a day for 8 weeks before and during IVF treatment
Number of subjects: 52
Study 24867068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive pregnant (HTP)
Number of subjects: 193
Study 23475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive pregnant (NTP)
Number of subjects: 193
Study 23475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive nonpregnant (HTNP)
Number of subjects: 193
Study 23475699 — intervention group
Group type: COMPARATOR
Intervention: Normotensive nonpregnant (NTNP)
Number of subjects: 193
Study 23475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive women during pregnancy
Number of subjects: 193
Study 23475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpregnant women with arterial hypertension (AH)
Number of subjects: 193
Study 23475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 193
Study 23475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 193
Study 21585170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L/d additional water intake
Number of subjects: 48
Study 21585170 — intervention group
Group type: COMPARATOR
Intervention: Usual fluid consumption (control group)
Number of subjects: 48
Study 19803239 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle‐sticking method combined with single‐finger meditation pushing therapy at pain points
Number of subjects: 150
Study 19803239 — intervention group
Group type: COMPARATOR
Intervention: Local application of Votalin Emulgel combined with Tuina
Number of subjects: 150
Study 16409461 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 2.5 mg b.i.d.
Number of subjects: 706
Study 16409461 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 5 mg b.i.d.
Number of subjects: 706
Study 16409461 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 10 mg b.i.d.
Number of subjects: 706
Study 16409461 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 20 mg b.i.d.
Number of subjects: 706
Study 16409461 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 30 mg b.i.d.
Number of subjects: 706
Study 16409461 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily (control)
Number of subjects: 706
Study 16409461 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (all doses)
Number of subjects: 706
Study 15156786 — intervention group
Group type: EXPERIMENTAL
Intervention: With visual control
Number of subjects: 6
Study 15156786 — intervention group
Group type: EXPERIMENTAL
Intervention: Without visual control
Number of subjects: 6
Study 11751721 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.21 mg/kg total intravenous dose in 15 minutes)
Number of subjects: 18
Study 9480620 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine vaginal suppository (200 mg polyvidonum‐iodine PVP) for 7 days
Number of subjects: 64
Study 7685895 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-eluting lead
Number of subjects: 35
Study 7685895 — intervention group
Group type: COMPARATOR
Intervention: Microporous platinum lead
Number of subjects: 35
Study 3327654 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus drug (colestipol plus niacin)
Number of subjects: 188
Study 3327654 — intervention group
Group type: COMPARATOR
Intervention: diet plus placebo
Number of subjects: 188
Study 31604475 — intervention group
Group type: EXPERIMENTAL
Intervention: lacosamide (up to 400 mg/day)
Number of subjects: 108
Study 31604475 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 108
Study 31604475 — intervention group
Group type: EXPERIMENTAL
Intervention: lacosamide
Number of subjects: 108
Study 30165438 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular angina (MVA)
Number of subjects: 81
Study 30165438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasospastic angina (VSA)
Number of subjects: 81
Study 30165438 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 81
Study 27291137 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (three sessions over 4 weeks)
Number of subjects: 80
Study 27291137 — intervention group
Group type: COMPARATOR
Intervention: Usual counseling from peer educators (control group)
Number of subjects: 80
Study 27291137 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing intervention and Usual counseling (both groups)
Number of subjects: 80
Study 23996969 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB + BMS
Number of subjects: 77
Study 23996969 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 77
Study 23996969 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 77
Study 22330261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral TAP block
Number of subjects: 80
Study 22330261 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration of trocar insertion sites
Number of subjects: 80
Study 19530009 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin pessary
Number of subjects: 54
Study 19530009 — intervention group
Group type: COMPARATOR
Intervention: Cervical cerclage
Number of subjects: 54
Study 17688642 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa‐HBV‐IPV vaccine
Number of subjects: 314
Study 16380886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients driving with binocular congruent scotomata within the central 30 degrees visual field
Number of subjects: 132
Study 16380886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients fulfilling legal requirements
Number of subjects: 132
Study 16380886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients with visual acuity below mandatory legal requirements
Number of subjects: 132
Study 16380886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients who stopped driving
Number of subjects: 132
Study 16380886 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected number of actively driving glaucoma patients not meeting legal requirements
Number of subjects: 132
Study 12392812 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated participants in wait-list, no-treatment, and placebo conditions)
Number of subjects: 29
Study 9638984 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO gene expression analysis using Northern blot hybridization and immunohistochemical staining
Number of subjects: 43
Study 9638984 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO gene expression analysis using reverse transcriptase‐polymerase chain reaction assay
Number of subjects: 43
Study 8184493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette‐Guérin (BCG) treatment for carcinoma in situ (CIS)
Number of subjects: 0
Study 8184493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette‐Guérin (BCG) treatment for prophylaxis
Number of subjects: 0
Study 8184493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette‐Guérin (BCG) treatment for tumor(s)
Number of subjects: 0
Study 2684039 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 6-mercaptopurine and weekly methotrexate (neutropenic group)
Number of subjects: 105
Study 2684039 — intervention group
Group type: COMPARATOR
Intervention: Daily 6-mercaptopurine and weekly methotrexate (non-neutropenic group)
Number of subjects: 105
Study 1093670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol 5.0 mg/day
Number of subjects: 3774
Study 1093670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol 1.0 mg/day
Number of subjects: 3774
Study 1093670 — intervention group
Group type: COMPARATOR
Intervention: Early endocrine treatment
Number of subjects: 3774
Study 1093670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3774
Study 30951497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) quartiles
Number of subjects: 1096
Study 30951497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin levels
Number of subjects: 1096
Study 27787342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentive intervention
Number of subjects: 0
Study 26313133 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (N=127)
Number of subjects: 255
Study 26313133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=128)
Number of subjects: 255
Study 26313133 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment for ACS (N=123)
Number of subjects: 255
Study 23703228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon and photograph montage storybook
Number of subjects: 100
Study 23703228 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no storybook)
Number of subjects: 100
Study 22379905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and extended-release epidural anesthesia with Ropivacaine 0.3%
Number of subjects: 40
Study 22379905 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and epidural anesthesia
Number of subjects: 40
Study 19407299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 9581
Study 19407299 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 9581
Study 17539714 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap associated with an acellular dermal matrix graft
Number of subjects: 10
Study 17539714 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap associated with a subepithelial connective tissue graft
Number of subjects: 10
Study 15475417 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimen 1
Number of subjects: 0
Study 15475417 — intervention group
Group type: COMPARATOR
Intervention: Treatment regimen 2
Number of subjects: 0
Study 15869585 — intervention group
Group type: EXPERIMENTAL
Intervention: rFXIII (50 U kg(‐1))
Number of subjects: 50
Study 15869585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10600077 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) using hand instruments
Number of subjects: 359
Study 10600077 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorations using rotary instruments and amalgam
Number of subjects: 359
Study 10600077 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorations using rotary instruments
Number of subjects: 359
Study 8757381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (500 mg suppositories administered 12 and 2 hours before surgery, and every 8 hours until the third postoperative day)
Number of subjects: 22
Study 8757381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (500 mg suppositories)
Number of subjects: 22
Study 8757381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (suppositories administered 12 and 2 hours before surgery, and every 8 hours until the third postoperative day)
Number of subjects: 22
Study 1682907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microgram/kg
Number of subjects: 6
Study 1682907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microgram/kg
Number of subjects: 6
Study 1682907 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 6807681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (100 mg) for 24 hours
Number of subjects: 8
Study 6807681 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (200 mg) for 24 hours
Number of subjects: 8
Study 6807681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol + Indomethacin (100 + 200 mg) for 24 hours
Number of subjects: 8
Study 6807681 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet
Number of subjects: 8
Study 6807681 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium intake
Number of subjects: 8
Study 31142454 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from randomised clinical trials
Number of subjects: 0
Study 31142454 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30534562 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impressions
Number of subjects: 24
Study 30534562 — intervention group
Group type: COMPARATOR
Intervention: Traditional impressions (Control)
Number of subjects: 24
Study 30534562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Digital and Traditional)
Number of subjects: 24
Study 27358067 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (n=29)
Number of subjects: 384
Study 27358067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 384
Study 24698578 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Scapular Manipulation (MSM)
Number of subjects: 97
Study 24698578 — intervention group
Group type: COMPARATOR
Intervention: Traction-Countertraction (TCT)
Number of subjects: 97
Study 22990854 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri NCIMB 30242 capsules
Number of subjects: 127
Study 22990854 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 127
Study 20423743 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate/high-protein (HPLC) diet
Number of subjects: 6
Study 20423743 — intervention group
Group type: COMPARATOR
Intervention: Starvation
Number of subjects: 6
Study 20423743 — intervention group
Group type: COMPARATOR
Intervention: Mixed-carbohydrate diet
Number of subjects: 6